Navigation Links
Eureka Therapeutics raises $21 million in series c to expand cancer immunotherapy pipeline
Date:9/23/2014

Eureka Therapeutics, Inc. announced today that the Company has secured $21 million in a Series C Financing. The new funding will be used to expand the Company's cancer immunotherapy pipeline and advance its lead programs to clinical development. New investor Yuan Capital led the round, with participation from Majuven and all existing major investors, including Acorn Campus Ventures, Suma Venture and Harbinger Venture Capital.

Eureka is engaged in the discovery and development of fully-human antibodies engineered to mimic the functions of a T cell receptor, a key component of the immune system. These therapeutic antibodies are designed to recognize proteins residing inside of cancer cells, and mobilize a patient's immune system to recognize and kill the diseased cell.

"This new funding will allow us to expand and advance our drug pipeline, as well as explore the synergistic effects of our drug candidates with other immunotherapies and immune modulators," said Cheng Liu, PhD, President and CEO of Eureka Therapeutics. "This moves us closer to our goal of providing cancer patients with safer and more effective treatments through novel immunotherapies."

"We are pleased to have the continued confidence and support of our existing investors, and we welcome our new investors," added Dr. Liu.

Earlier this year, the Company announced a license agreement with Novartis for the development and commercialization of ESK1, a preclinical-stage monoclonal antibody for the treatment of leukemia and other cancers. The antibody, targeting the intracellular protein WT1, was developed under a collaborative effort between Eureka Therapeutics and Memorial Sloan-Kettering Cancer Center.


'/>"/>

Contact: Elisa Pan
admin@eurekainc.com
510-654-7045
Eureka Therapeutics, Inc.

Source:Eurekalert

Page: 1

Related biology news :

1. EUREKA grant to fund development of new optogenetic technique for mapping neural networks at UMMS
2. Study shows Hera Therapeutics compound combats HPV types that cause most cervical cancer
3. Human Longevity, Inc. and Celgene Cellular Therapeutics Sign License Agreement to Develop and Commercialize Placental Stem Cell Population, PSC-100 for Multiple Therapeutic Applications
4. Splice-switching oligonucleotide therapeutics is new method for editing gene transcript
5. Industry group release testing recommendations for oligonucleotide-based therapeutics
6. Nanomerics, UCL, H Lundbeck & Exeter University to research new brain therapeutics
7. Next-generation glaucoma therapeutics hold considerable promise
8. FASEB announces 2014 SRC: Translational Neuroimmunology: From Mechanisms to Therapeutics
9. Emerging class of therapeutics represents a coming wave for developers and manufacturers
10. Natura Therapeutics product shown to improve decision making skills in older adults
11. Arcturus Therapeutics Raises $5 Million in Series A Funding to Maintain its Momentum in Nominating Lead Clinical Candidate in 2014
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/16/2017)... , May 16, 2017   Bridge ... health organizations, and MD EMR Systems , ... development partner for GE, have established a partnership ... Portal product and the GE Centricity™ products, including ... EMR. These new integrations will ...
(Date:4/19/2017)... York , April 19, 2017 ... as its vendor landscape is marked by the presence ... market is however held by five major players - ... Together these companies accounted for nearly 61% of the ... the leading companies in the global military biometrics market ...
(Date:4/13/2017)... SANTA MONICA, Calif. , April 13, 2017 /PRNewswire/ ... New York will feature emerging and ... Innovation Summits. Both Innovation Summits will run alongside the ... variety of speaker sessions, panels and demonstrations focused on ... east coast,s largest advanced design and manufacturing event will ...
Breaking Biology News(10 mins):
(Date:10/7/2017)... ... October 06, 2017 , ... ... for microscopy and surface analysis, Nanoscience Instruments is now expanding into Analytical ... broad range of contract analysis services for advanced applications. Services will leverage ...
(Date:10/7/2017)... , Oct. 6, 2017  The 2017 ... of three scientists, Jacques Dubochet, Joachim Frank ... developments in cryo-electron microscopy (cryo-EM) have ... within the structural biology community. The winners worked ... can now routinely produce highly resolved, three-dimensional images ...
(Date:10/6/2017)... D.C. (PRWEB) , ... October 06, 2017 , ... ... will host a lunch discussion and webinar on INSIGhT, the first-ever adaptive clinical ... Principal Investigator, Dana-Farber Cancer Institute. The event is free and open to the ...
(Date:10/5/2017)... , ... October 05, 2017 , ... Understanding the microbiome, ... frontiers in human health. Gut Love: You Are My Future, the newest exhibit on ... perspective as it explores the human condition through the lens of the gut microbiome. ...
Breaking Biology Technology: